What is PRTA's current stock price?

PRTA (Prothena Corporation plc) is currently trading at $9.83 with a market cap of $514.6M.

What sector is Prothena Corporation plc in?

Prothena Corporation plc (PRTA) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is PRTA a good stock to buy?

Analysts have a Hold consensus on PRTA with a price target of $19.00. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

PRTA Prothena Corporation plc

Healthcare

$9.83+4.46%ClosedMarket Cap: $514.6M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

1.69

P/S

8.88

EV/EBITDA

-2.36

DCF Value

$3.52

FCF Yield

-15.8%

Div Yield

0.0%

Margins & Returns

Gross Margin

46.8%

Operating Margin

-217.9%

Net Margin

-260.9%

ROE

-49.9%

ROA

-43.2%

ROIC

-39.4%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$51.1M	$32.7M	$—
Q4 null	$21.0K	$-21.6M	$—
FY null	$9.7M	$-244.1M	$—
Q3 null	$2.4M	$-36.5M	$—

Analyst Ratings

View All

Consensus

Hold

Target (Consensus)

$19.00

Target (Median)

$19.00

Target Range

$19.00 - $19.00

2 Strong Buy1 Buy2 Hold0 Sell1 Strong Sell

CitizensMarket Outperform

2026-05-08

RBC CapitalSector Perform

2026-02-20

CitizensMarket Outperform

2025-12-01

HC Wainwright & Co.Buy

2025-11-07

RBC CapitalSector Perform

2025-11-07

Trading Activity

Insider Trades

View All

WELCH DANIEL Gdirector

SellFri May 15

Selkoe Dennis J.director

SellFri May 15

Ekman Larsdirector

SellFri May 15

Dunn William H. Jr.director

SellFri May 15

Cooke Shanedirector

SellFri May 15

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

-0.23

Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. The company was founded in 2012 and is based in Dublin, Ireland.

Peers